Search

everythinglearnresearchcommunity

for

Search:↓

Treatment with biologic agents can significantly improve psoriasis symptoms, and blood biomarkers could potentially predict individual patient's response to treatment.

OR101 may effectively treat atopic dermatitis and similar skin conditions.

Interferon alfa-2a is effective for treating cutaneous T cell lymphoma but has significant side effects.

Interferon, especially alfa interferon, is an effective treatment for cutaneous T-cell lymphoma with manageable side effects.

Dimethyl fumarate speeds up wound healing in IL-36Ra deficient mice by reducing NET formation and oxidative stress.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.

Beta-trace protein may help diagnose and predict treatment response in certain nerve disorders.

Intestinal intraepithelial lymphocytes are crucial for gut immunity and maintaining the mucosal barrier.

Higher IL-17A and IL-23 levels are linked to alopecia areata severity and could help in tracking and treating the disease.

Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.

The ID2 gene can help distinguish between sensitizers and irritants in skin cells.

A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.

PLAU and SerpinB2 affect cell death differently in various forms of leprosy and could be targets for new treatments.

IL-36α helps in growing new hair follicles when healing wounds, potentially aiding in hair growth.

IL6 is linked to higher risk of heart disease in people with a certain mouth condition.

Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.

IL-17-producing γδ T cells help improve bone healing.

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

Removing Ctip2 in skin cells causes skin inflammation similar to atopic dermatitis.

Certain genetic variations in IL-16 may increase the risk of alopecia areata.

Targeted therapy with Ustekinumab significantly improved a skin condition called ILVEN, which is caused by mutations in the CARD14 gene.

IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.

QLT0267 stops hair follicle cell growth and movement.

Blocking certain immune signals can reduce skin damage from radiation therapy.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

Blocking IL-8 can reduce skin rashes from cancer treatment.

SIG-1451 could be a promising new treatment for atopic dermatitis.

Tph cells are linked to the severity of systemic lupus erythematosus.